ResearcherLudwig-Maximilians-Universität MünchenActive in the last 2 years

Victoria Probst

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-8038-7351; OpenAlex author ID A5084260142. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2024: 1 paper

Papers 1

Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Last author DOI 10.1016/j.ejca.2024.113926 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Danmei Zhang · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Michael Haas · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Lena Weiss · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Klara Dorman · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Kathrin Heinrich · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Volker Heinemann · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Dirk Waldschmidt · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Michael Quante · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Stefan Hubert Boeck · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗
Christoph Benedikt Westphalen · 1 shared paper, 2024 · strength 0.18
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.